ARIAD’s AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor

News   Nov 03, 2009

 
 ARIAD’s AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
 
 
 

RELATED ARTICLES

First-in-Human Trial Evaluating Ebola Treatment Begins

News

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114

READ MORE

Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

News

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.

READ MORE

Ataxin Links Long Term-Memory and Neurodegeneration

News

Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in motor neuron disease (MND)

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE